Over the last few years, scientists and entrepreneurs have flocked to developing medicines that target RNA, the genetic ...

In 1957, just four years after Francis Crick and other scientists solved the riddle of DNA’s structure—the now famous double ...

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

Yale researchers have developed a new and safe family of RNA-editing tools that utilize an RNA-targeting activity that they ...

The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not ...

In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.

The US Food and Drug Administration (FDA) has approved Dawnzera (donidalorsen) for prophylaxis to prevent attacks of ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...

As aging progresses, the quality of DNA and proteins inside cells declines, which is known to be the cause of various ...

Skyhawk Therapeutics, Inc., a leader in the discovery and development of small molecules that modulate RNA expression, today ...